Title:Association of ABO Gene rs2073823 Polymorphism with Microvascular Complications, sP-Selectin Levels and Lipid Profile in Type 2 Diabetes
Volume: 22
Issue: 2
Author(s): Haithem Rauf Mohammed, Rym Ben Othman*, Zahraa Saad Hatef, Mohamed Kacem Ben Fradj and Haifa Abdesselem
Affiliation:
- Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
- Institut National de Nutrition
et de Technologie Alimentaire de Tunis, service A, Tunis, Tunisia
Keywords:
Type 2 diabetes, ABO gene rs2073823 polymorphism, microvascular complications, diabetic retinopathy, sP-selectin, diabetic neuropathy.
Abstract:
Introduction: Type 2 diabetes (T2D) is a prevalent metabolic disorder linked to chronic
inflammation and endothelial dysfunction, which contributes to the development of microvascular
complications (MVCs) such as diabetic retinopathy (DR) and diabetic neuropathy (DN). Genetic
factors, including variations in the ABO gene, may influence these complications. This study
aimed to investigate the association between the ABO rs2073823 polymorphism and the risk of
MVCs in patients with T2D, as well as its impact on inflammatory biomarkers, endothelial markers,
and lipid profiles.
Materials and Methods: We conducted an exploratory study involving 96 T2D Iraqi patients
(Asian Arabic), examining the distribution of the ABO rs2073823 polymorphism and its correlation
with MVCs. We assessed levels of inflammatory markers (TNF-α, IL-6, sE-selectin, sP-selectin),
glycemic markers, renal function biomarkers, and lipid profiles. Adjustment was made for confounding
factors including age, gender, body mass index, duration of diabetes, and hypertension.
Results: Among the participants, 75% had MVCs, including DR (42%) and DN (65%). The ABO
rs2073823 “A/A” genotype was associated with a reduced risk of MVCs under co-dominant
(OR=0.16, p=0.045) and recessive models (OR=0.14, p=0.031). This protective effect remained
significant after adjusting for confounding factors (OR=0.11, p=0.022). The “A/A” genotype was
also linked to lower levels of total cholesterol, LDL-cholesterol, triglycerides, and sP-selectin. Patients
with MVCs exhibited significantly higher levels of TNF-α, IL-6, and sP-selectin.
Conclusion: The ABO rs2073823 polymorphism, particularly the “A/A” genotype, is associated
with a decreased risk of MVCs in T2D patients and influences lipid metabolism and inflammatory
markers. These findings suggest a genetic basis for the susceptibility to MVCs and highlight the
role of the ABO gene in modulating inflammation and endothelial function in T2D. Further research
is needed to validate these associations and explore potential therapeutic implications.
